Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Why these 3 ASX healthcare shares could get a boost from the federal budget
Australian Clinical Labs (ASX:ACL) share price falls despite tripling profits and beating guidance
Top broker just rated these 3 ASX shares as buys
This top fund manager just called these leading ASX shares a buy
2 ASX 200 shares benefitting from the surge in COVID tests
In the green: Here are the 5 best ASX healthcare shares of 2021
What’s going on with the Australian Clinical Labs (ASX:ACL) share price lately?
Brokers name 3 ASX shares to buy today
|25 Mar 2022||$0.1200||100.00%||Interim||21 Apr 2022|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Australian Clinical Labs Ltd is engaged in the provision of pathology services. Its services include all routine pathology tests, advanced pathology, First-trimester screening, and Non-Invasive prenatal testing, Chemical pathology, Haematology, Histopathology, Immunology, Serology and microbiology, Functional pathology, Commercial drug, and alcohol testing. The company has its operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.
|16 May 2022||$5.69||$0.21||3.83%||440,010||$5.50||$5.74||$5.50|
|13 May 2022||$5.48||$0.29||5.59%||607,455||$5.02||$5.48||$5.02|
|12 May 2022||$5.19||$0.11||2.17%||626,088||$4.99||$5.19||$4.95|
|11 May 2022||$5.08||$0.02||0.40%||719,111||$5.09||$5.12||$4.87|
|10 May 2022||$5.06||$0.07||1.40%||179,502||$4.97||$5.13||$4.95|
|09 May 2022||$4.99||$-0.11||-2.16%||243,949||$5.01||$5.08||$4.88|
|06 May 2022||$5.10||$-0.10||-1.92%||92,817||$5.14||$5.14||$5.07|
|05 May 2022||$5.20||$0.01||0.19%||188,067||$5.19||$5.22||$5.14|
|04 May 2022||$5.19||$0.06||1.17%||282,496||$5.16||$5.22||$5.09|
|03 May 2022||$5.13||$0.01||0.20%||199,940||$5.15||$5.17||$5.03|
|02 May 2022||$5.12||$-0.03||-0.58%||358,858||$5.15||$5.20||$5.11|
|29 Apr 2022||$5.15||$0.12||2.39%||77,963||$5.08||$5.16||$5.07|
|28 Apr 2022||$5.03||$-0.04||-0.79%||147,266||$5.00||$5.13||$5.00|
|27 Apr 2022||$5.07||$-0.02||-0.39%||139,088||$4.95||$5.11||$4.94|
|26 Apr 2022||$5.09||$-0.11||-2.12%||197,906||$5.20||$5.20||$5.04|
|22 Apr 2022||$5.20||$-0.09||-1.70%||244,057||$5.25||$5.37||$5.16|
|21 Apr 2022||$5.29||$0.00||0.00%||158,700||$5.29||$5.29||$5.19|
|20 Apr 2022||$5.29||$0.11||2.12%||291,625||$5.18||$5.32||$5.14|
|21 Apr 2022||Michael Alscher||Issued||5||$29,995||
Dividend Reinvestment Plan (DRP).
|21 Apr 2022||Andrew Dutton||Issued||1||$9,598||
Dividend Reinvestment Plan (DRP).
|21 Apr 2022||Melinda McGrath||Issued||15||$80,155||
Dividend Reinvestment Plan (DRP).
|21 Apr 2022||Melinda McGrath||Issued||50||$254,816||
Dividend Reinvestment Plan (DRP).
|25 Feb 2022||Michael Stanford||Buy||8||$36,960||
|22 Nov 2021||Mark Haberlin||Buy||22||$98,988||
|25 May 2021||Melinda McGrath||Issued||247||$899,997||
Issue of securities. 247,252 - Performance rights.
|Mr Michael Thomas Alscher||Non-Executive ChairmanNon-Executive Director||Dec 2020||
Mr Alscher was appointed Chair of ACL's predecessor corporate vehicle Clinical Laboratories Pty Ltd in 2015 following its acquisition by Crescent Capital Partners in 2015. Mr Alscher was appointed a Director of ACL on 19 December 2020 and Chair of ACL as part of the IPO process on 19 December 2020. Mr Alscher is the Managing Partner and founder of Crescent, a leading Australian private equity investment firm, specialising in high growth companies and certain industry sectors such as healthcare. Mr Alscher is the current Chair of Cardno Limited, National Dental Care Limited, National Home Doctor Service Pty Ltd and is a Non-Executive Director of Clearview Wealth Limited. Mr Alscher's former director roles include Chair of Cover-More Group Limited, LifeHealthcare Group Limited and Director of Metro Performance Glass Limited. Prior to founding Crescent in 2000, Mr Alscher was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles.
|Dr Michael Philip Stanford||Non-Executive Director||Apr 2021||
Mr Stanford has over 25 years of Non-Executive Director experience across a range of industries including healthcare services, diagnostics, biotech, pharmaceutical, property, aged care and higher education. Mr Stanford is the current Chair of Diabetes Australia, an Independent Non-Executive Director of NorthWest Healthcare Property Management Limited and Nucleus Network Limited, and a Senior Advisor at Medibank Private Limited. Mr Stanford's former roles include Non-Executive Director for ACL between 2016 and 2019, Healthscope Limited, Virtus Health Limited, and Deputy Chancellor of Curtin University. He was in Group Chief Executive Officer roles for 23 years including 16 years at St John of God Health Care. Mr Stanford has also received a Member of the Order of Australia for his service to the health sector, to tertiary education and in the community of Western Australia.
|Dr Leanne Rowe||Non-Executive Director||Apr 2021||
Dr Rowe has been a Non-Executive Director of ACL since 28 April 2021. Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Dr Rowe is currently Chair of Nexus Hospitals and a Non-Executive Director of Japara Healthcare Limited, Doctor Care Anywhere Group PLC, the Medical Indemnity Protection Society and MIPS Insurance. Previously she was Chair of the Royal Australian College of General Practitioners and a Non-Executive Director of Medibank Private, I-MED Radiology Network, GMHBA, Australian Health Management, Barwon Health and Beyond Blue.
|Mr Andrew Mark Rendle Dutton||Non-Executive Director||Apr 2021||
Mr Dutton has been a Non-Executive Director of ACL since 28 April 2021. Mr Dutton has 30 years of management, business development and technology experience across Australia, Asia and Europe. Mr Dutton is the current Chair of Land Registry Services and was recently an Advisor to FinancialForce APJ. He has had Chief Executive Officer and Board experience globally and within Australia. Mr Dutton's former roles include Chair of NVOI Pty Ltd and SAI Global Pty Ltd; Chief Executive Officer at Land Registry Services and Integrated Research Limited; Managing Director of the Asia Pacific/Japan region for VMware Inc.; and senior executive positions at IBM, Computer Associates, BEA Systems Inc., Lend Lease and Norwich Union Financial Services Group including roles as CFO, CMO, CRO and Divisional Heads. At IBM, Mr Dutton was elected to the Worldwide Senior Leadership Team.
|Mr Nathanial Jonothan Thomson||Non-Executive Director||Dec 2020||
Mr Thomson has been a Non-Executive Director of ACL's predecessor corporate vehicle, Clinical Laboratories Pty Ltd, since April 2018. Mr Thomson was appointed a Non-Executive Director of ACL on 19 December 2020. Mr Thomson is a Partner at Crescent, a leading Australian private equity investment firm. Mr Thomson has over 20 years of experience in strategy consulting, private equity and investment banking. He has consulting experience from his prior role at McKinsey & Co. Mr Thomson is a current Director of Cardno Limited, National Dental Care Limited, Clearview Wealth Limited and National Home Doctor Service Pty Ltd. Mr Thomson's former director roles include Deputy Chair of Cover-More Group Limited and a Non-Executive Director of Metro Performance Glass Limited.
|Mr Mark Haberlin||Non-Executive Director||Apr 2021||
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mr Haberlin is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Mr Haberlin is also an Independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Limited. Previously, Mr Haberlin was the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific.
|Ms Melinda Leigh McGrath||Chief Executive OfficerExecutive Director||Dec 2020||
Ms McGrath has been the Chief Executive Officer and Executive Director of ACL's predecessor corporate vehicle, Clinical Laboratories Pty Ltd since 2015. Ms McGrath was appointed an Executive Director of ACL on 19 December 2020. Ms McGrath has more than 30 years' experience in healthcare with over 20 years of experience in chief executive roles and over 13 years of experience in pathology CEO roles. Ms McGrath has played a lead role in the organisation's transformation, building ACL's scale and operational performance improvement over the past six years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology and SunDoctors. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Ms McGrath was Chief Executive Officer of QML Pathology (part of Healius) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Ms McGrath held various chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Ms McGrath has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services; and a superannuation fund, UC Super.
|Ms Eleanor Padman||Company Secretary||
|James Davison||Chief Financial Officer||
|Eleanor Padman||Company Secretary||
|Crescent Capital Partners||39,270,974||19.46%|
|HSBC Custody Nominees (Australia) Limited||27,912,181||13.83%|
|Citicorp Nominees Pty Limited||24,293,812||12.04%|
|National Nominees Limited||18,924,054||9.38%|
|Instanz Nominees Pty Ltd||14,036,045||6.95%|
|CCP Trusco 1 Pty Ltd||13,158,261||6.52%|
|CCP Trusco 5 Pty Ltd||6,207,125||3.08%|
|CCP Trusco 2 Pty Ltd||5,765,804||2.86%|
|CCP Trusco 4 Pty Ltd||5,533,472||2.74%|
|JP Morgan Nominees Australia Pty Limited||3,624,902||1.80%|
|BNP Paribas Noms Pty Ltd||3,544,378||1.76%|
|Perpetual Corporate Trust Ltd||3,074,742||1.52%|
|Perpetual Corporate Trust Ltd I||2,635,495||1.31%|
|Brispot Nominees Pty Ltd||2,541,938||1.26%|
|Hsbc Custody Nominees (Australia) Limited I||2,031,155||1.01%|
|Morgan Stanley Australia Securities (Nominee) Pty Limited||980,557||0.49%|
|CS Fourth Nominees Pty Limited||911,576||0.45%|
|UBS Nominees Pty Ltd||830,226||0.41%|